Our results tend to support these overall findings of reliable remodelling of DBM to new bone. The histological analysis showed significant new bone formation and decreasing residual DBM material in ...
As previously disclosed, in late Q3 2022, the Company began to experience material supply issues related to its ALLOCYTE ® Advanced Cellular Bone Matrix (“ALLOCYTE”) product line. The supply ...
Molecular Matrix, a privately held company that arose from the University of California, Davis, received FDA approval for its Osteo-P bone graft substitute technology. Osteo-P is a non-mineralized, ...
SAN FRANCISCO & PARSIPPANY, N.J.--(BUSINESS WIRE)--Ossium Health®, a bioengineering company that established a first-of-its-kind bone marrow banking platform, has entered into a collaborative ...
Osteocytes, the most abundant cells in bone tissue, have long been underestimated in their functional capacity. Traditionally viewed as passive entities, recent research has illuminated their pivotal ...
Cerapedics Inc., a global, commercial-stage orthopedics company dedicated to redefining the path to bone repair, today announced U.S. Food and Drug Administration (FDA) approval for an expansion to ...
Nine patients (6 male and 3 female, 30 to 64 years old) that were scheduled for elective removal of dorsal instrumentation hardware over a 12-month time period were included in our study. Indications ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results